Paraphilia Clinical Trial
— ESPARAOfficial title:
Study of Maintenance of the Efficiency and Adverse Effects of Pharmacological Treatments in Sex Offenders With Paraphilia
This research concerns the evaluation of the maintenance of the efficiency and incidence of adverse effects of pharmacological treatments in sex offenders with paraphilia. Despite the increasing use of pharmacological treatments in these indications, there are few data to indicate which sex offender populations benefit from which pharmacological treatments and which adverse events are observed, particularly with anti-androgens or antidepressant treatments that are widely used in these subjects. A recent Cochrane study showed that psychodynamic treatment is less effective in terms of sexual delinquency compared to probation alone and has not shown significant efficacy of cognitive behavioral therapy (CBT) compared to the lack of treatment, except for a study in which anti-androgen therapy was associated with CBT. Another recent study concluded that the tolerance, even of anti-androgenic drugs, was uncertain, as all studies were small and of limited duration, and new research is needed in the future. Further research demonstrating the efficacy of SSRIs in the treatment of paraphilic disorders is still needed and long-term studies are lacking. Their use for this indication is still off label. As far as we know, this cohort should be the largest population of paraphilic sex offenders studied for the longest time to date in a field where research is insufficient. This large sample receiving routine care and followed for 3 years should allow to analyse the maintenance of the effectiveness of the pharmacological treatments received (SSRIs or anti-androgens), and their tolerance. In addition, this analysis of clinical practices should be crucial to improve the knowledge of the indications for these treatments, which could possibly be reviewed with respect to their effectiveness and tolerance, especially in the most serious cases of paraphilic sex offenders.
Status | Not yet recruiting |
Enrollment | 250 |
Est. completion date | October 2027 |
Est. primary completion date | December 2026 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 18 Years to 65 Years |
Eligibility | Inclusion Criteria: Man - At least one sex offence - Paraphilia (DSM-5 criteria ) - Receiving pharmacological treatment ( ISRS or anti-androgen or none of them) - Age between 18 and 65 years - Patient 100% covered by social security Exclusion Criteria: - no consent - female - aged under 18 or over 65 years - subject receiving simultaneous ISRS and anti-androgen treatment before enrolment - incarcerated - Subject under guardianship (patients under curatorship may however be included), - no social security registration - contraindications or allergies to treatments |
Country | Name | City | State |
---|---|---|---|
France | Hôpital Cochin | Paris |
Lead Sponsor | Collaborator |
---|---|
Assistance Publique - Hôpitaux de Paris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Sexual desire and activity intensity scale | ISRS Group and no pharmacological treatment group : Treatment efficiency : Sexual desire intensity and scale to measure deviant and non deviant sexual behavior symptoms. (Lickert's scale, scale range : 0 to 7) | Change from inclusion at 36 months | |
Primary | Incidence of adverse events | Anti-Androgen Group and no pharmacological treatment group : Report of any adverse event: the type, frequency, time of occurrence of adverse events | 36 months | |
Secondary | Sexual desire intensity scale | Anti-Androgen Group : Treatment efficiency : Sexual desire intensity and scale to measure deviant and non deviant sexual behavior symptoms | Every 3 months up to 36 months | |
Secondary | Incidence of adverse events | ISRS Group: Report of any adverse event: the type, frequency, time of occurrence of adverse events | Every 3 months up to 36 months | |
Secondary | Clinical factors | All groups : Maintenance of efficacy and incidence of side effects will be analysed taking into account clinical factors listed above. | Every 3 months up to 36 months | |
Secondary | Psychological factors | All groups : Maintenance of efficacy and incidence of side effects will be analysed taking into account psychological factors listed above. | Every 3 months up to 36 months | |
Secondary | Demographic factors | All groups : Maintenance of efficacy and incidence of side effects will be analysed taking into account demographic factors listed above. | Every 3 months up to 36 months | |
Secondary | Relapse rate | Must stay rare event (low expected number, sexual offense risk evaluated in literature around 10%when the treatment is controlled regularly, the relapses are statistically analysed if the numbers is sufficient, but it can not be a principal assessment because of their rarity). | Every 3 months up to 36 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT05482412 -
Acute Intense Paraphilic Desire (DSM-V) Down-Regulation Via taVNS Neuro-Modulation [Transcutaneous Afferent Vagus Nerve] With Future Operative Implant Consideration
|
N/A | |
Completed |
NCT01743209 -
Descriptive Epidemiology Study for Patients With Paraphilia Sex Offenders and Receiving Androgen Antagonists
|
N/A | |
Terminated |
NCT00379626 -
Cognitive and Hormonal Treatment of Sex Offenders
|
Phase 1 |